Sub-Q Inc.

Despite the best intentions and brightest innovation, start-ups haven’t been able to tap into the huge potential presented by the vascular closure market. But the opportunity simply is too big for the

After an initial warm welcome for first-generation femoral artery closure devices—including a few high-profile exits—sales have stalled. Early devices are flawed, indicating the technical challenge is

At the top of the industry, consolidation has frozen out much additional M[TKTK] at the bottom—particularly in biotech—consolidation usually provides more problems than answers. By Roger Longman If yo